194 related articles for article (PubMed ID: 38163666)
21. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
[TBL] [Abstract][Full Text] [Related]
22. Intracellular Delivery of Anti-Kirsten Rat Sarcoma Antibodies Mediated by Polymeric Micelles Exerts Strong
Rafael D; Montero S; Carcavilla P; Andrade F; German-Cortés J; Diaz-Riascos ZV; Seras-Franzoso J; Llaguno M; Fernández B; Pereira A; Duran-Lara EF; Schwartz S; Abasolo I
ACS Appl Mater Interfaces; 2023 Mar; 15(8):10398-10413. PubMed ID: 36795046
[TBL] [Abstract][Full Text] [Related]
23. Targeting KRAS in pancreatic cancer: new drugs on the horizon.
Bannoura SF; Uddin MH; Nagasaka M; Fazili F; Al-Hallak MN; Philip PA; El-Rayes B; Azmi AS
Cancer Metastasis Rev; 2021 Sep; 40(3):819-835. PubMed ID: 34499267
[TBL] [Abstract][Full Text] [Related]
24. Glycoproteomic Analysis of Urinary Extracellular Vesicles for Biomarkers of Hepatocellular Carcinoma.
Li D; Jia S; Wang S; Hu L
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770959
[TBL] [Abstract][Full Text] [Related]
25. Mass Spectrometry-Based Glycoproteomic Workflows for Cancer Biomarker Discovery.
Doud EH; Yeh ES
Technol Cancer Res Treat; 2023; 22():15330338221148811. PubMed ID: 36740994
[TBL] [Abstract][Full Text] [Related]
26. Glycoproteomics-based signatures for tumor subtyping and clinical outcome prediction of high-grade serous ovarian cancer.
Pan J; Hu Y; Sun S; Chen L; Schnaubelt M; Clark D; Ao M; Zhang Z; Chan D; Qian J; Zhang H
Nat Commun; 2020 Dec; 11(1):6139. PubMed ID: 33262351
[TBL] [Abstract][Full Text] [Related]
27. Benchmark of site- and structure-specific quantitative tissue N-glycoproteomics for discovery of potential N-glycoprotein markers: a case study of pancreatic cancer.
Lu H; Xiao K; Tian Z
Glycoconj J; 2021 Apr; 38(2):213-231. PubMed ID: 33835347
[TBL] [Abstract][Full Text] [Related]
28. Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer.
Brychta N; Krahn T; von Ahsen O
Clin Chem; 2016 Nov; 62(11):1482-1491. PubMed ID: 27591291
[TBL] [Abstract][Full Text] [Related]
29. Mass Spectrometry-Based Chemical and Enzymatic Methods for Global Analysis of Protein Glycosylation.
Xiao H; Suttapitugsakul S; Sun F; Wu R
Acc Chem Res; 2018 Aug; 51(8):1796-1806. PubMed ID: 30011186
[TBL] [Abstract][Full Text] [Related]
30. KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas.
Krasinskas AM; Chiosea SI; Pal T; Dacic S
Mod Pathol; 2014 Feb; 27(2):262-70. PubMed ID: 23887294
[TBL] [Abstract][Full Text] [Related]
31. Heterogeneity of KRAS Mutations in Pancreatic Ductal Adenocarcinoma.
Hashimoto D; Arima K; Yokoyama N; Chikamoto A; Taki K; Inoue R; Kaida T; Higashi T; Nitta H; Ohmuraya M; Hirota M; Beppu T; Baba H
Pancreas; 2016 Sep; 45(8):1111-4. PubMed ID: 26967456
[TBL] [Abstract][Full Text] [Related]
32. Advances in mass spectrometry driven O-glycoproteomics.
Levery SB; Steentoft C; Halim A; Narimatsu Y; Clausen H; Vakhrushev SY
Biochim Biophys Acta; 2015 Jan; 1850(1):33-42. PubMed ID: 25284204
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of Chronic Pancreatitis and Murine Pancreatic Intraepithelial Neoplasia by a Dual Inhibitor of c-RAF and Soluble Epoxide Hydrolase in LSL-KrasG¹²D/Pdx-1-Cre Mice.
Liao J; Hwang SH; Li H; Liu JY; Hammock BD; Yang GY
Anticancer Res; 2016 Jan; 36(1):27-37. PubMed ID: 26722025
[TBL] [Abstract][Full Text] [Related]
34. The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features.
Ma Z; Zhang Y; Deng C; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2022 Jan; 163(1):e73-e85. PubMed ID: 32739163
[TBL] [Abstract][Full Text] [Related]
35. N-linked glycosylation profiling of pancreatic cancer serum using capillary liquid phase separation coupled with mass spectrometric analysis.
Zhao J; Qiu W; Simeone DM; Lubman DM
J Proteome Res; 2007 Mar; 6(3):1126-38. PubMed ID: 17249709
[TBL] [Abstract][Full Text] [Related]
36. Mass profiling of serum to distinguish mice with pancreatic cancer induced by a transgenic Kras mutation.
Hocker JR; Mohammed A; Aston CE; Brewer M; Lightfoot SA; Rao CV; Hanas JS
Int J Cancer; 2013 Dec; 133(11):2662-71. PubMed ID: 23712558
[TBL] [Abstract][Full Text] [Related]
37. Sialic acid linkage-specific quantitative N-glycoproteomics using selective alkylamidation and multiplex TMT-labeling.
Yang H; Tian Z
Anal Chim Acta; 2022 Oct; 1230():340391. PubMed ID: 36192063
[TBL] [Abstract][Full Text] [Related]
38. Serum N-Glycome analysis reveals pancreatic cancer disease signatures.
Vreeker GCM; Hanna-Sawires RG; Mohammed Y; Bladergroen MR; Nicolardi S; Dotz V; Nouta J; Bonsing BA; Mesker WE; van der Burgt YEM; Wuhrer M; Tollenaar RAEM
Cancer Med; 2020 Nov; 9(22):8519-8529. PubMed ID: 32898301
[TBL] [Abstract][Full Text] [Related]
39. Quantitative analysis of N-glycans from human alfa-acid-glycoprotein using stable isotope labeling and zwitterionic hydrophilic interaction capillary liquid chromatography electrospray mass spectrometry as tool for pancreatic disease diagnosis.
Giménez E; Balmaña M; Figueras J; Fort E; Bolós C; Sanz-Nebot V; Peracaula R; Rizzi A
Anal Chim Acta; 2015 Mar; 866():59-68. PubMed ID: 25732693
[TBL] [Abstract][Full Text] [Related]
40. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
